Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to $51.3 million.

  • Silence Therapeutics' Cash from Investing Activities rose 23686.88% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.5 million, marking a year-over-year increase of 18289.83%. This contributed to the annual value of -$22.0 million for FY2024, which is 21384.89% down from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Cash from Investing Activities is $51.3 million, which was up 23686.88% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Cash from Investing Activities ranged from a high of $66.1 million in Q4 2024 and a low of -$49.9 million during Q1 2024
  • Its 5-year average for Cash from Investing Activities is -$102593.9, with a median of -$44076.0 in 2022.
  • As far as peak fluctuations go, Silence Therapeutics' Cash from Investing Activities surged by 5288724.22% in 2023, and later crashed by 3217759.44% in 2024.
  • Quarter analysis of 5 years shows Silence Therapeutics' Cash from Investing Activities stood at $6.0 million in 2021, then tumbled by 420.8% to -$19.3 million in 2022, then surged by 102.46% to $474120.0 in 2023, then soared by 13846.89% to $66.1 million in 2024, then dropped by 22.44% to $51.3 million in 2025.
  • Its Cash from Investing Activities was $51.3 million in Q3 2025, compared to -$1.6 million in Q2 2025 and -$44.4 million in Q1 2025.